36 results about "Tumor-Related Protein" patented technology

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor associated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.

The invention belongs to the technical field of medicines, and relates to an antigen covalently bound chitosan nanoparticle-based nasal immune carrier and a preparation method thereof. The carrier is composed of a nanoparticle and an antigen, the antigen is covalently bound to the surface of the nanoparticle, and the nanoparticle is prepared by adopting a raw material chitosan and its derivatives; and the antigen is selected from from infectious diseases or tumors related proteins or polypeptides. The carrier can significantly improve the neck lymph node targeting of people nasally dosed with the antigen proteins or polypeptides, enhances the mucosal and systemic immune response, has the advantages of simple preparation, stable process, high antigen utilization rate, difficult antigen shedding, benefiting of the improvement of the cervical lymph node transportation of the antigens, good nasal immune effect and no nasal mucosa toxicity, and is suitable for preventing respiratory infectious diseases.

Expression vectors are described that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-χ-glutamic acid synthetase complex (pgsBCA) of a Bacillus sp. strain, and genes that encode virion capsid proteins, tumor-associated proteins of human papillomavirus. Methodology for preparing the foregoing vectors, vaccines and transformed microorganisms are also described.

The invention relates to novel prodrugs or conjugates of the general formula (Ia)

in which La, n, R and D have the definitions given in the description and which have a structural motif reduced to an asparagine derivative as cleavage site for tumour-associated proteases such as legumain, in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are released by legumain cleavage, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers. Reduction of the legumain-cleavable substrate peptide sequence to an asparagine derivative as structural motif, as a result of slowed legumain cleavage, achieves an increase in stability in the lysosomes of healthy organs while simultaneously maintaining the high anti-tumour effect.

The invention provides an Ultra-VEGF-trap immune fusion protein, which can be the protein in 1) or 2): 1) a protein composed of the amino acid sequence shown in SEQID.1; and 2) an anti-tumor related protein that is derived from 1) and is obtained by subjecting the amino acid sequence shown in SEQID.1 to substitution and/or deletion and/or adding by one or several amino acids. The invention also provides a construction method and application of the Ultra-VEGF-trap immune fusion protein. The immune fusion protein provided in the invention totally blocks the transduction pathway of VEGFs/VEGFRs, and has enormous value for treatment of multiple malignant tumors.

The invention discloses a human CYR61 protein Ser188 site phosphorylation antigen, an antibody and a preparation method and an application thereof, and relates to the technical field of antibodies andthe preparation. The antibody is prepared for an immune animal with an antigenic peptide through the active amino acid sequence shown in SEQ ID NO: 1. The phosphorylation antibody is useful for studying and kinase mediating phosphorylation and exploring various biological functions of CYR61 protein. In the practical application, the antibody can be utilized to study the action mechanism of the human CYR61 protein specific site phosphorylation modification in a specific biological event or a disease generation and development process and can also be used for detecting the difference in the expression of tumor-associated proteins after drug use to provide a potential action target for diagnosis and treatment of clinical tumor diseases.

The invention discloses a tumour-associated protein detection method based on monomolecular counting. The tumour-associated protein detection method provided by the invention includes the following steps: 1) the tumour-associated protein molecule to be detected is captured onto a glass sheet by specificity interaction of ligand and receptor or specificity interaction of antibody and antigen, thenfluorescent labelled antibody directing to the tumour-associated protein molecule to be detected is added on the glass sheet, so as to obtain the glass sheet to be detected; 2) the glass sheet to be detected obtained by the step 1) is placed on the objective lens of a total internal reflection microscope to carry out detection of tumour-associated protein. The invention belongs to protein detection method, has the advantages of convenient operation, high detection sensibility, less sample usage and no enzyme amplification compared with similar technology and can detect low concentration protein molecule.

The present invention relates to a method for improved diagnosis of cervical lesions based on detection of gene products encoded by the INK4a gene locus. According to the present invention an improvement in diagnosis may be achieved by assessing the presence or absence or the level of overexpression of at least two different gene products encoded by the INK4a gene locus. In another aspect the present invention relates to peptides derived from cell cycle regulatory proteins, the expression of which is altered in association with tumors in individuals. These peptides according to the present invention may be used for detection and therapy of tumors. For detection purposes the peptides may for example be used to detect antibodies directed against said peptides. In therapeutic respect the peptides may be used for immunotherapy or vaccination approaches. In therapeutic and diagnostic respect the peptides may be used in combination with one or more peptides derived from tumor associated proteins.

The invention discloses a human CYR61 protein Ser167 locus phosphorylated antigen and antibody, as well as preparation methods and application thereof, and relates to the technical field of antibody and preparation thereof. The antibody is obtained for preparing an antigen peptide immune animal through active amino acid sequence shown in SEQ ID NO: 1. The phosphorylated antibody provided by the invention is conducive to the research of kinase which mediates the antibody to conduct phosphorylation and the discussion on various biological functions of CYR61 protein, facilitates researching the action mechanism of human CYR61 protein specific locus phosphorylation in specific biological events or disease occurrence and development process in actual application, can also be used for detectingthe difference of tumor-related protein expression after drug use, and provides potential action targets for the diagnosis and treatment of clinical tumor diseases.

The invention relates to an immunity biological treatment that extractive protein from cancer organism or cancer cell, wherein it uses ammonia sulfate to deposit the protein component from cancer organism slurry or cancer cell crack liquid; the deposit contains requco protein group and relative cancer antigens; removes salt, concentrates, freezes and dries, the extractive can be directly prepared into injection of external agent to excite the immunity cell to the cancer patient, and the immunity system will recognize and kill cancer cell.

The invention relates to a technical invention which can be used for detecting a protein expression profile of a tissue slice. According to the technical invention, after a plurality of different antibodies are simultaneously bonded with a plurality of proteins to be detected of a tumor tissue, an identification V-D-J sequence subjected to PCR (Polymerase Chain Reaction) amplification is hybridized with an antibody gene chip, and the protein expression profile of the tumor tissue is displayed through a hybridization result; and certain protein in-situ expression statuses are selectively displayed through immunohistochemistry. The technical invention can be used for clinically detecting individual tumor related protein expression profiles of patients, solving the problem that a large number of protein expressions are subjected to in-situ detection for tissue slices, and directly applying a proteome research result to a clinical diagnosis process, thereby being an important premise for realizing individual treatment of diseases.

The invention discloses a multi-tumor combined detection kit. The multi-tumor combined detection kit comprises fluorescent microspheres capable of performing time resolution, a signal amplification system, a first tumor-associated protein, a sample to-be-detected object, a second tumor-associated protein and polymer fluorescent coding microspheres. The invention further discloses a use method of the kit. The method comprises the following steps: adding a to-be-detected sample; processing incubation oscillation, forming a reaction mixture of macromolecular fluorescence codes, second tumor-associated protein, a to-be-detected object, first tumor-associated protein and fluorescent microspheres capable of being subjected to time resolution; using a time-resolved flow type fluorescence detection device for carrying out high-throughput test; conveying sample liquid and sheath liquid to the flowing chamber together; after to-be-detected liquid particles sequentially pass through a flowing chamber capillary tube detection area, a first laser is activating, enabling a first laser fluorescence detector to collect fluorescence signals while a second laser is activated, and after short-life background fluorescence decay disappears, starting a second laser time-resolved fluorescence detection unit to collect signals for analysis and processing.

Compositions, methods, and uses of recombinant calreticulin protein that is modified to be expressed on the cell surface are presented. Preferably, the recombinant calreticulin protein is presented on the antigen presenting cell surface with a tumor associated protein to increase immunogenicity of the tumor cell in the tumor microenvironment.

A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.

he disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.